NCT06743243
Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia
At risk: Primary completion moved 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 8 words
- Primary completion pushed from Oct 30, 2026 to Dec 30, 2026
- Secondary endpoints revised (3)
- Collaborators: details revised at 1 of 4 entries
Notable Lead sponsor: Kim, Young Sung to Seok Kyeong Ohv2 Show 6 more changesShow less
- Trial status: Not Yet Recruiting to Enrolling by Invitation
- Start date changed from estimate of Mar 2025 to Jul 23, 2025
- Primary completion date: Oct 2026 to Oct 30, 2026
- Study completion date: Oct 2026 to Dec 30, 2026
- Site contact updated
- Collaborators revised (4)
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Gastric pH right after endotracheal intubation
Timeframe: right after endotracheal intubation
Secondary (3)
Change of oral, esophageal and gastric pH
Gastric volume evaluated by Ultrasound
Risk of aspiration(pH < 2.5, Gastric volume > 0.4mL/kg) and frequency of complications(aspiration etc.)
Arms and interventions
Group TExperimental
Tegoprazan OD tab. 50 mg PO + Saline 20 ml IV, one hour before general anesthesia.
Group FActive comparator
Famotidine 20 mg/10 ml + Saline 10 ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.
Group CPlacebo comparator
Tegoprazan OD tab. 50 mg placebo PO + Saline 20 ml IV, one hour before general anesthesia.
Drugs: Tegoprazan, Famotidine, Placebo
Sites
1 site in 1 country
- Korea University Medical Center, Guro HospitalSeoul, South Korea